Revolutionary therapies and the rapid adoption of AI make it clear that the life sciences industry stands on the brink of a new dawn, while wrestling dwindling investor confidence in light of the IRA and a new R&D tax regime. How will the industry mobilize the necessary capital and resources needed to tackle these developments?